Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target

Krzysztof W. Pankiewicz; Steven E. Patterson; Paul L. Black; Hiremagalur N. Jayaram; Dipesh Risal; Barry M. Goldstein; Lieven J. Stuyver; Raymond F. Schinazi

doi:10.2174/0929867043455648

Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target

Krzysztof W. Pankiewicz
, Steven E. Patterson
, Paul L. Black
, Hiremagalur N. Jayaram
, Dipesh Risal
, Barry M. Goldstein
, Lieven J. Stuyver
, Raymond F. Schinazi

Research output: Contribution to journal › Review article › peer-review

63 Scopus citations

Abstract

IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

Original language	English (US)
Pages (from-to)	887-900
Number of pages	14
Journal	Current medicinal chemistry
Volume	11
Issue number	7
DOIs	https://doi.org/10.2174/0929867043455648
State	Published - Apr 2004
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.2174/0929867043455648

Find It

Find It at U of M Libraries

Cite this

@article{59cdbdcec9024a25905fde042cfa5ee1,

title = "Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target",

abstract = "IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.",

author = "Pankiewicz, \{Krzysztof W.\} and Patterson, \{Steven E.\} and Black, \{Paul L.\} and Jayaram, \{Hiremagalur N.\} and Dipesh Risal and Goldstein, \{Barry M.\} and Stuyver, \{Lieven J.\} and Schinazi, \{Raymond F.\}",

year = "2004",

month = apr,

doi = "10.2174/0929867043455648",

language = "English (US)",

volume = "11",

pages = "887--900",

journal = "Current medicinal chemistry",

issn = "0929-8673",

publisher = "Bentham Science Publishers",

number = "7",

}

TY - JOUR

T1 - Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target

AU - Pankiewicz, Krzysztof W.

AU - Patterson, Steven E.

AU - Black, Paul L.

AU - Jayaram, Hiremagalur N.

AU - Risal, Dipesh

AU - Goldstein, Barry M.

AU - Stuyver, Lieven J.

AU - Schinazi, Raymond F.

PY - 2004/4

Y1 - 2004/4

N2 - IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

AB - IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

UR - https://www.scopus.com/pages/publications/1842431902

UR - https://www.scopus.com/pages/publications/1842431902#tab=citedBy

U2 - 10.2174/0929867043455648

DO - 10.2174/0929867043455648

M3 - Review article

C2 - 15083807

AN - SCOPUS:1842431902

SN - 0929-8673

VL - 11

SP - 887

EP - 900

JO - Current medicinal chemistry

JF - Current medicinal chemistry

IS - 7

ER -

Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this